Investment Institute
Análisis macroeconómico

Escaping COVID-19: Will vaccines be sufficient?

  • 19 Mayo 2021 (5 min de lectura)

Key points

  • We conduct a detailed assessment of the impact of vaccines and viruses on a large number of countries
  • We find that in only a handful of cases is collective immunity even plausible. In most cases it looks unlikely – and in several impossible – with the current vaccines. This suggests the virus could become endemic
  • Vaccines appear highly successful in reducing virus severity. But even if perfect, which does not appear the case, hospitalisations of unvaccinated groups would likely be too large to allow the virus to spread freely
  • This suggests an ongoing need for non-pharmaceutical interventions, even in mostly-vaccinated countries. Yet we see the risk of countries lifting restrictions too far
  • This risks the re-emergence of the virus and a need to increase restrictions. Precautionary household and company behaviour would likely follow. We include this in our baseline forecasts for later this year
  • A risk scenario where an immune-resistant new variant emerges also exists. This would require a return of more significant intervention, which would deliver a more material economic shock to baseline forecasts.

Related Articles

Análisis macroeconómico

Eurozone public debt sustainability: Make hay while the sun shines

  • por François Cabau
  • 25 Agosto 2023 (5 min de lectura)
Análisis macroeconómico

UK public debt sustainability: Post–Truss truths

  • por Modupe Adegbembo
  • 12 Junio 2023 (3 min de lectura)
Análisis macroeconómico

El impacto desigual de la inflación: Actuación de los gobiernos

  • por David Page
  • 25 Octubre 2022 (5 min de lectura)

    Advertencia sobre riesgos

    El valor de las inversiones y las rentas derivadas de ellas pueden disminuir o aumentar y es posible que los inversores no recuperen la cantidad invertida originalmente.

    Clientes Profesionales

    El sitio web de AXA INVESTMENT MANAGERS ESPAÑA está destinado exclusivamente a clientes profesionales tal y como son definidos en la Directiva 2014/65/EU (Directiva sobre Mercados de Instrumentos Financieros). Para una mayor información sobre la disponibilidad de los fondos AXA IM, por favor consulte con su asesor financiero o diríjase a la página web de la CNMV